A Study of Neuromyelitis Optica Spectrum Disorders (NMOSD): Disease Pattern Based on Antibody Status

Area of Science:

• Neuroimmunology
• Neurology
• Autoimmune Diseases

Background:

• Neuromyelitis optica (NMO) and related disorders are central nervous system demyelinating conditions with autoimmune underpinnings.
• Aquaporin-4 antibodies (AQP4-Ab) are key biomarkers in identifying specific NMO spectrum disorder (NMOSD) subtypes.
• Understanding serological status is crucial for accurate diagnosis and management of NMOSD.

Purpose of the Study:

• To investigate the clinical, laboratory, and imaging characteristics of NMOSD patients stratified by AQP4-Ab serology.
• To compare demographic, clinical, and prognostic factors between AQP4-Ab-positive and AQP4-Ab-negative NMOSD cohorts.

Main Methods:

• Retrospective analysis of 46 NMOSD patients with known AQP4-Ab status.
• Inclusion based on Wingerchuk criteria (2006) for NMO and a minimum 1-year follow-up.
• Comparison of clinical features, CSF analysis, MRI findings, relapse rates, and recovery between seropositive and seronegative groups.

Main Results:

• 56.5% of NMOSD patients were AQP4-Ab positive.
• Seropositive patients exhibited a higher mean age of onset (36.8 vs 28.8 years) and a different male to female ratio (1:7.7 vs 1:1.2).
• Higher relapse rates (84.6% vs 55%) and poorer recovery (15%) were observed in AQP4-Ab positive NMOSD, though statistical significance for all features was not reached.

Conclusions:

• Significant differences in age, gender distribution, and prognosis exist between AQP4-Ab-positive and AQP4-Ab-negative NMOSD.
• AQP4-Ab serological status is a critical factor influencing NMOSD patient outcomes.
• Antibody status can guide initial treatment strategies for NMOSD, particularly after the first attack.